MHR
HRMY icon

Matthew Hamilton Rosenberg’s Harmony Biosciences HRMY Stock Holding History

Matthew Hamilton Rosenberg’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1
Closed -$32 – 888
2023
Q4 		$32 Hold
1
– – ﹤0.01% 910
2023
Q3 		$33 Hold
1
– – ﹤0.01% 925
2023
Q2 		$35 Buy
+1
New +$35 ﹤0.01% 949

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Matthew Hamilton Rosenberg's HRMY Position: Q1 2024 in Review

Matthew Hamilton Rosenberg sold out of Harmony Biosciences (HRMY) in Q1 2024, closing a stake of 1 share — an estimated $32 sold.

Matthew Hamilton Rosenberg first reported a position in HRMY in Q2 2023 and held it in 3 quarters. The position peaked at $35 in Q2 2023. 208 funds tracked by Wall St. Rank hold HRMY as of Q1 2024.

  • Matthew Hamilton Rosenberg reported no remaining Harmony Biosciences position as of Q1 2024 after selling out during the quarter.
  • Matthew Hamilton Rosenberg sold 1 Harmony Biosciences share in Q1 2024, an estimated $32.
  • Matthew Hamilton Rosenberg first reported a position in Harmony Biosciences in Q2 2023 and held it in 3 quarters.
  • Matthew Hamilton Rosenberg's Harmony Biosciences position peaked at $35 in Q2 2023.
  • 208 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2024.

Based on Matthew Hamilton Rosenberg's 13F filing for Q1 2024, filed 22 Apr 2024.